Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Pension (2017 - 2025)

Historic Pension for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $3.0 million.

  • Innate Pharma's Pension rose 1345.5% to $3.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.0 million, marking a year-over-year increase of 1345.5%. This contributed to the annual value of $2.9 million for FY2024, which is 1107.6% up from last year.
  • As of Q2 2025, Innate Pharma's Pension stood at $3.0 million, which was up 1345.5% from $2.9 million recorded in Q4 2024.
  • Innate Pharma's Pension's 5-year high stood at $4.7 million during Q2 2021, with a 5-year trough of $2.6 million in Q4 2022.
  • Moreover, its 5-year median value for Pension was $2.9 million (2022), whereas its average is $3.1 million.
  • Its Pension has fluctuated over the past 5 years, first plummeted by 9988.76% in 2021, then surged by 1345.5% in 2025.
  • Innate Pharma's Pension (Quarter) stood at $3.4 million in 2021, then fell by 23.56% to $2.6 million in 2022, then rose by 0.95% to $2.6 million in 2023, then grew by 11.08% to $2.9 million in 2024, then rose by 3.45% to $3.0 million in 2025.
  • Its Pension was $3.0 million in Q2 2025, compared to $2.9 million in Q4 2024 and $2.7 million in Q2 2024.